
Mayrim V Rios Perez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/279457/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CES2 sustains HNF4Î \pm expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Molecular Metabolism, 2022, 56, 101426.	6.5	14
2	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precision Oncology, 2020, 4, 426-436.	3.0	9
3	Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Cell Death and Differentiation, 2019, 26, 382-393.	11.2	49
4	Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. Laboratory Investigation, 2018, 98, 947-956.	3.7	30
5	Extremity lipoblastoma in an adolescent. Journal of Pediatric Surgery Case Reports, 2018, 30, 11-13.	0.2	0
6	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2018, 24, 5883-5894.	7.0	76
7	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2017, 16, 662-670.	4.1	17
8	Transforming Growth Factor-Î ² Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clinical Cancer Research, 2016, 22, 4934-4946.	7.0	31
9	<i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2016, 22, 6021-6030.	7.0	56
10	Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. Cureus, 2015, 7, e423.	0.5	5